NASDAQ:NPCE

NeuroPace (NPCE) Stock Forecast, Price & News

$7.89

+0.09 (+1.15%)

(As of 09/22/2023 ET)

Compare

Today's Range: $7.71
▼
$8.00
50-Day Range: $4.00
▼
$9.39
52-Week Range: $1.22
▼
$9.50

Volume: 29,973 shs
Average Volume: 112,816 shs
Market Capitalization: $204.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

NeuroPace MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1.4% Upside
$8.00 Price Target
Short Interest: Healthy
4.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.53) to ($1.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

803rd out of 963 stocks

Surgical & Medical Instruments Industry

84th out of 97 stocks

1.3

Analyst's Opinion

Consensus Rating
NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, NeuroPace has a forecasted upside of 1.4% from its current price of $7.89.
Amount of Analyst Coverage
NeuroPace has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.28% of the float of NeuroPace has been sold short.
Short Interest Ratio / Days to Cover
NeuroPace has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in NeuroPace has recently decreased by 7.80%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
NeuroPace does not currently pay a dividend.
Dividend Growth
NeuroPace does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NPCE.

3.2

News and Social Media Coverage

News Sentiment
NeuroPace has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for NeuroPace this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NeuroPace insiders have not sold or bought any company stock.
Percentage Held by Insiders
27.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.69% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for NeuroPace are expected to grow in the coming year, from ($1.53) to ($1.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NeuroPace is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NeuroPace is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NeuroPace has a P/B Ratio of 5.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NeuroPace (NASDAQ:NPCE) Stock

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NPCE Price History

30 days | 90 days | 365 days | Advanced Chart

NPCE Stock News Headlines

September 20, 2023 | finance.yahoo.com

NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference

August 25, 2023 | msn.com

Morgan Stanley Upgrades NeuroPace (NPCE)

September 24, 2023 | Altimetry (Ad)

WARNING: Seven millionaires to trigger sudden market panic?

The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.

August 24, 2023 | finance.yahoo.com

NeuroPace to Participate in Upcoming Investor Conferences

August 13, 2023 | finance.yahoo.com

Rainbows and Unicorns: NeuroPace, Inc. (NASDAQ:NPCE) Analysts Just Became A Lot More Optimistic

August 9, 2023 | finanznachrichten.de

NeuroPace, Inc.: NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

August 8, 2023 | finance.yahoo.com

NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

July 19, 2023 | finance.yahoo.com

NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market

September 24, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

July 18, 2023 | finance.yahoo.com

NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023

June 29, 2023 | finanznachrichten.de

NeuroPace, Inc.: NeuroPace Announces CEO Transition

June 28, 2023 | finance.yahoo.com

NeuroPace Announces CEO Transition

June 14, 2023 | benzinga.com

People Are Lining Up For Elon Musk's Neuralink Brain Implant — Here's How You Can Invest In Brain Technology Startups

May 25, 2023 | finanznachrichten.de

NeuroPace, Inc.: NeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales

May 24, 2023 | finance.yahoo.com

NeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales

May 18, 2023 | msn.com

NeuroPace's Return On Capital Employed Overview

May 6, 2023 | msn.com

Morgan Stanley Maintains NeuroPace (NPCE) Underweight Recommendation

May 5, 2023 | msn.com

Recap: NeuroPace Q1 Earnings

May 4, 2023 | finance.yahoo.com

NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

April 27, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT) and NeuroPace (NPCE)

April 17, 2023 | finance.yahoo.com

NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023

April 17, 2023 | finance.yahoo.com

Further Upside For NeuroPace, Inc. (NASDAQ:NPCE) Shares Could Introduce Price Risks After 39% Bounce

April 3, 2023 | finance.yahoo.com

NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference

March 30, 2023 | finance.yahoo.com

NeuroPace (NASDAQ:NPCE) adds US$17m to market cap in the past 7 days, though investors from a year ago are still down 44%

March 6, 2023 | finance.yahoo.com

NeuroPace, Inc. (NASDAQ:NPCE) Q4 2022 Earnings Call Transcript

March 4, 2023 | benzinga.com

NeuroPace Stock (NASDAQ:NPCE), Dividends

March 4, 2023 | seekingalpha.com

NeuroPace reports Q4 results, co guides FY 2023 revenue above consensus

See More Headlines

Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

NPCE Company Calendar

Last Earnings: 8/08/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NPCE
CUSIP: N/A
CIK: 1528287
Web: www.neuropace.com
Phone: 650-237-2700
Fax: N/A
Employees: 169
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +1.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,080,000.00
Net Margins: -77.25%
Pretax Margin: -77.25%
Return on Equity: -133.74%
Return on Assets: -38.30%

Debt

Debt-to-Equity Ratio: 2.58
Current Ratio: 7.52
Quick Ratio: 6.65

Sales & Book Value

Annual Sales: $45.52 million
Price / Sales: 4.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.40 per share
Price / Book: 5.64

Miscellaneous

Outstanding Shares: 25,860,000
Free Float: 18,749,000
Market Cap: $204.04 million
Optionable: Not Optionable
Beta: 1.97

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Ms. Irina Ridley (Age 37)
Chief Legal Officer & Corp. Sec.
Comp: $499.31k

Dr. Martha J. Morrell (Age 66)
Chief Medical Officer
Comp: $555.87k

Mr. Joel D. Becker (Age 55)
CEO & Director

Ms. Rebecca L. Kuhn (Age 62)
CFO, VP of Fin. & Admin. and Assistant Sec.

Ms. Kelley Nicholas
VP of Sales

Ms. Irene Thomas (Age 54)
VP of HR

Mr. Andre G. Marquette
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NPCE Stock - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings or view top-rated stocks.
What is NeuroPace's stock price forecast for 2023?: 2 equities research analysts have issued 1 year price objectives for NeuroPace's stock. Their NPCE share price forecasts range from $6.00 to $10.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts.
How have NPCE shares performed in 2023?: NeuroPace's stock was trading at $1.49 on January 1st, 2023. Since then, NPCE stock has increased by 429.5% and is now trading at $7.89.
View the best growth stocks for 2023 here.
When is NeuroPace's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NPCE earnings forecast.
How were NeuroPace's earnings last quarter?: NeuroPace, Inc. (NASDAQ:NPCE) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.11. The business earned $16.51 million during the quarter, compared to analysts' expectations of $12.74 million. NeuroPace had a negative net margin of 77.25% and a negative trailing twelve-month return on equity of 133.74%.
What guidance has NeuroPace issued on next quarter's earnings?: NeuroPace updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $59.00 million-$61.00 million, compared to the consensus revenue estimate of $52.85 million.

When did NeuroPace IPO?: (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.
What is NeuroPace's stock symbol?: NeuroPace trades on the NASDAQ under the ticker symbol "NPCE."
Who are NeuroPace's major shareholders?: NeuroPace's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Kent Lake Capital LLC (0.58%), BlackRock Inc. (0.14%) and Renaissance Technologies LLC (0.07%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer, Irina Ridley and Orbimed Advisors Llc.
View institutional ownership trends.
How do I buy shares of NeuroPace?: Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NeuroPace's stock price today?: One share of NPCE stock can currently be purchased for approximately $7.89.
How much money does NeuroPace make?: NeuroPace (NASDAQ:NPCE) has a market capitalization of $204.04 million and generates $45.52 million in revenue each year. The company earns $-47,080,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.
How many employees does NeuroPace have?: The company employs 169 workers across the globe.
How can I contact NeuroPace?: The official website for the company is www.neuropace.com. The company can be reached via phone at 650-237-2700 or via email at investors@neuropace.com.

This page (NASDAQ:NPCE) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial